Bioconjugates of synthetic apelin polypeptides
View Patent ↗The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I′ (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
1. A bioconjugate or a multimer thereof, comprising:
a) a peptide or polypeptide having the following formula V (SEQ ID NO: 6):
wherein:
X1 is the N-terminus of the polypeptide and is either absent or is selected from R, Q, A and K;
X5 is L, A, K, D or F;
wherein the side chain of the two Cysteines (C) are linked together via a covalent bond forming a disulfide (—S—S—);
X7 is H, A, K, F, P, N or E;
X11 is M, A, F, Y, L or K; and
X13 is the C-terminus and is absent or is selected from F, I, A, K, H and E;
or an amide, an ester or a salt of the polypeptide; and
b) a half-life extending moiety;
wherein the half-life extending moiety is a Fc domain which is fused to said polypeptide via a linker and wherein the linker has the following Formula:
-[GGGGS]n-, n is 1, 2 or 3 (SEQ ID NO: 16) or the linker is GG or GS.
2. The bioconjugate according to claim 1 wherein the half-life extending moiety is a FcLALA modified Fc fragment with a LALA mutation (L234A, L235A).
3. The bioconjugate according to claim 2 wherein the polypeptide is: Q-R-P-R-L-C*-H-K-G-P-M-C*-F (SEQ ID NO: 17).
4. A Combination comprising a therapeutically effective amount of a bioconjugate according to claim 1 , and one or more therapeutically active co-agent.
5. A combination according to claim 4 wherein the co-agent is selected from inotropes, beta adrenergic receptor blockers, HMG-Co-A reductase inhibitors, angiotensin II receptor antagonists, angiotensin converting enzyme (ACE) Inhibitors, calcium channel blockers (CCB), endothelin antagonists, renin inhibitors, diuretics, ApoA-I mimics, anti-diabetic agents, obesity-reducing agents, aldosterone receptor blockers, endothelin receptor blockers, aldosterone synthase inhibitors (ASI), a CETP inhibitor, anti-coagulants, relaxin, BNP (nesiritide) and/or a NEP inhibitor.
6. A pharmaceutical composition comprising a therapeutically effective amount of a bioconjugate according to claim 1 , and one or more pharmaceutically acceptable carriers.
7. The bioconjugate according to claim 1 wherein X1 is A or Q; and the peptide is fused to the half-life extending moiety via its A or Q N-terminus.
8. The bioconjugate according to claim 1 wherein X5 is L.
9. The bioconjugate according to claim 1 wherein X7 is H.
10. The bioconjugate according to claim 1 wherein X13 is absent or F.
11. The bioconjugate according to claim 1 having any one of SEQ ID NO: 100, 101 and 116 to 126.
12. The bioconjugate according to claim 1 having SEQ ID NO: 100.